-
3740 E Southern Ave, Ste 210
Mesa, AZ 85206 -
Monday–Friday, 9:00 AM – 6:00 PM MST
by appointment only -
Saturday
By Appointment -
Sunday
Closed
You have tried the medications. You have waited the six to eight weeks they said it would take to feel a difference. You have been through the adjustments, the side effects, and the appointments where nothing meaningfully changed. If you are at the point where a provider has mentioned Spravato treatment as a possible next step, you are likely carrying a specific kind of exhaustion — the kind that comes from trying hard and not getting better.
The questions you have about what this treatment actually involves are reasonable ones. This guide answers them directly, from what a session feels like to what the full treatment schedule looks like across weeks, so you can make an informed decision without the fog of uncertainty.
Spravato occupies an unusual space in mental health treatment. It is FDA-approved, covered by most major insurance plans, and backed by significant clinical research. Yet most people who are referred for it have never heard of it before their provider brought it up, and the information available online tends to be either highly technical or alarming in tone.
The result is a gap between what Spravato treatment actually involves in a clinical setting and what people expect before they arrive. That gap drives a lot of the hesitation around pursuing it, and it is almost entirely avoidable with accurate information.
For a broader understanding of why treatment-resistant depression sometimes requires a different clinical approach altogether, the guide on treatment-resistant depression covers why standard antidepressants stop working for some people and what that means for next steps.
Spravato is the brand name for esketamine, a nasal spray derived from ketamine that works on an entirely different neurological pathway than conventional antidepressants. Where most antidepressants target serotonin or norepinephrine, esketamine targets NMDA receptors in the brain’s glutamate system.
This distinction matters clinically. If a person has tried multiple antidepressants without meaningful improvement, those medications were likely all working on the same pathway. Spravato treatment bypasses that pathway entirely, which is why it can produce results for people who have not responded to anything else.
According to the National Institute of Mental Health (NIMH), esketamine is an FDA-approved medication for treatment-resistant depression that acts rapidly, typically within a couple of hours, to relieve depression symptoms. People usually continue to take an oral antidepressant alongside it to maintain improvement over time.
It is important to understand that Spravato treatment is not a standalone therapy. It is administered alongside an oral antidepressant as part of a coordinated care plan, and it is only available through certified healthcare settings that meet specific federal requirements.
Not everyone with depression is a candidate for Spravato. The clinical criteria are specific, and a thorough evaluation is required before any treatment begins.
You may be a candidate for Spravato treatment if:
A comprehensive psychiatric evaluation is the first step. Your provider will review your full treatment history, current medications, medical background, and whether Spravato is the right fit for your specific clinical picture. This is not a checklist — it is a thorough clinical conversation.
For a full overview of how depression is evaluated and treated as part of an integrated approach to care, the depression treatment page outlines what that process looks like from the first appointment forward.
Preparation for Spravato treatment begins before you ever arrive at the office for your first dose. Understanding what is required in advance makes the process significantly smoother.
You should not eat for at least two hours before your session, and you should avoid drinking liquids other than water for at least thirty minutes beforehand. Eating too close to a session can increase the likelihood of nausea during treatment.
Your provider will review your current medications before treatment begins. Some medications interact with esketamine, and your provider will advise on any adjustments needed before your first session.
You cannot drive on the day of your Spravato treatment. This is a firm requirement under the FDA’s REMS program, not a suggestion. Plan for someone to pick you up, or arrange another form of transportation home. This applies to every session, not just the first one.
Most patients find the two-hour monitoring period more comfortable with a few simple items on hand. A blanket, comfortable clothing, a phone or tablet for quiet entertainment, and earphones are commonly recommended. Some patients find that listening to calm music during the dissociative phase of the session makes the experience more manageable.
This is the question most people have and the one that is hardest to find a clear answer to. Here is what a typical session looks like from arrival to discharge.
When you arrive, your provider will check your blood pressure before administering the medication. If your blood pressure is elevated above a specific threshold, the session may be postponed. Your provider will also ask about your current mood and any changes since your last appointment.
Spravato is self-administered as a nasal spray under your provider’s direct supervision. You hold the device to one nostril and press to release the spray, then repeat with the other nostril depending on your prescribed dose. Your provider will guide you through the process on your first session.
Within minutes of administration, you may begin to experience dissociative effects. These are expected, documented, and temporary. Common experiences include:
These effects vary significantly from person to person and from session to session. They are not dangerous in a supervised clinical setting and typically begin to resolve within thirty to forty-five minutes of administration. You will be monitored throughout.
After administration, you remain in the clinical setting for a minimum of two hours. According to the FDA, Spravato is available only through certified healthcare settings and patients must be monitored by a healthcare provider for at least two hours after each treatment session.
This monitoring period exists because the medication can cause sedation and blood pressure changes that require clinical observation before a patient is cleared to leave. Most patients rest comfortably during this time. Some find the period restful. Others use it to listen to music, journal, or simply sit quietly. By the end of the monitoring period, most of the dissociative effects will have resolved, and your provider will assess whether you are stable enough to be discharged.
Once cleared, you leave with your arranged transportation. You should plan to rest for the remainder of the day. Avoid making important decisions, operating machinery, or engaging in demanding cognitive tasks until you have had a full night of sleep following your session.
Spravato treatment follows a structured protocol that unfolds in phases over weeks and months.
During the first four weeks of treatment, sessions are scheduled twice weekly. This frequency is designed to build and sustain the neurological changes associated with esketamine’s mechanism of action. Two sessions per week for four weeks means eight sessions in total during the induction phase.
Beginning in week five, sessions shift to once weekly for four weeks, followed by a transition to once every one to two weeks depending on your individual clinical response. The maintenance phase is ongoing and adjusted based on how well your depression is responding to treatment.
Unlike conventional antidepressants, which typically take four to six weeks to produce any noticeable effect, Spravato treatment can produce meaningful symptom relief within hours to days of the first session for some patients. This speed of response is one of the most clinically significant features of esketamine.
That said, responses vary. Some people notice a meaningful shift early. Others find that improvement builds more gradually across multiple sessions. The absence of an immediate response in the first session or two does not mean the treatment is not working.
Spravato treatment does not replace your oral antidepressant. Throughout the protocol, your provider continues to manage your full medication plan, monitor your progress, and make adjustments as needed. The two treatments work together rather than one replacing the other.
For more detail on how Spravato fits into a broader depression treatment plan, the Spravato service page outlines the full clinical protocol and what integrated care looks like from evaluation through ongoing treatment.
According to Mayo Clinic, esketamine nasal spray may cause dissociation, dizziness, nausea, increased blood pressure, sedation, and tingling sensations. Most side effects are temporary and resolve during or shortly after the monitoring period.
Here is what patients commonly report and how to prepare:
Nausea is one of the more common side effects and is often related to eating too close to a session. Following the fasting guidelines significantly reduces its likelihood. If nausea is persistent, your provider can prescribe anti-nausea medication to be taken before sessions.
The dissociative effects of Spravato can be surprising if you are not expecting them. Understanding that they are a normal, expected part of the treatment and that they will resolve during the monitoring period helps most patients navigate the experience more comfortably. Having a strategy for the monitoring period, whether that is music, an eye mask, or simply resting, makes a real difference.
Spravato temporarily raises blood pressure in many patients. Your provider measures your blood pressure before and after each session. Patients with significantly elevated blood pressure may have sessions postponed until their levels are within an appropriate range.
Feeling drowsy or mentally foggy after a session is common. This is the primary reason you cannot drive on treatment days, and it is why planning for a rest day following each session is strongly recommended rather than scheduling demanding activities immediately afterward.
Some patients experience a headache after the dissociative effects resolve. Staying hydrated before and after the session and resting afterward typically helps. If headaches are persistent across sessions, discuss this with your provider.
A typical session lasts approximately two to two and a half hours from arrival to discharge. This includes the pre-session blood pressure check, self-administration of the nasal spray, the dissociative and monitoring period, and a final clinical assessment before you are cleared to leave.
No. Spravato is required by federal regulation to be administered in a certified healthcare setting under direct clinical supervision. Your provider is present and monitoring you throughout the session. The monitoring requirement exists specifically to ensure patient safety.
No treatment works for everyone. Clinical trials have shown meaningful response rates, but some patients do not experience significant improvement. If the treatment is not producing results after an adequate trial, your provider will discuss alternative options with you. The goal is always to find the approach that works for your specific clinical situation.
Yes, and in fact Spravato is designed to be used alongside an oral antidepressant rather than as a replacement for it. Your provider will review your current medications before treatment begins to ensure there are no significant interactions and to coordinate your full medication plan.
Missing sessions during the induction phase can affect the consistency of the treatment protocol. If you need to reschedule, contact your provider as early as possible. Your provider will advise on the best way to maintain the treatment schedule and whether any adjustments to the protocol are needed.
Many major insurance plans cover Spravato for patients who meet the clinical criteria for treatment-resistant depression. Coverage requires prior authorization in most cases, which your provider’s office typically assists with before your first session. If you are in the Mesa, AZ area, the treatment-resistant depression in Mesa page has information about accessing Spravato locally including insurance considerations.
For most people who reach Spravato treatment, the path there has been long. Multiple medications. Multiple adjustments. A pattern of partial improvement at best and no improvement at all at worst. Coming into this treatment with that history means coming in with a specific kind of cautious hope — not optimism, exactly, but a willingness to try one more thing that is meaningfully different from what came before.
What makes Spravato treatment genuinely different is not just the mechanism. It is the speed. It is the fact that people who have been waiting years for something to shift sometimes feel a change within hours. It is the fact that it exists precisely for the people who have already tried everything else.
That does not mean it works for everyone. But it does mean that arriving for a first session with accurate expectations, a clear plan for the day, and an understanding of what the experience will actually feel like puts you in the best possible position to give it a real chance.
Disclaimer:This article is intended for informational and educational purposes only. It does not constitute medical advice, a diagnosis, or a treatment recommendation. Always consult a qualified healthcare provider for guidance specific to your individual circumstances. Spravato (esketamine) is an FDA-approved prescription medication that must be administered under clinical supervision.